the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Category | Publishers | Custom Research | E-mail Alert | About Us | Contact Us | Site Map |
 

* View All Categories
View Conferences
Japanese Korean Chinese

Market Research Report

Global Biomaterial Market (2009-2014)

Published by Markets and Markets Contact us : +1-860-674-8796
Published 2009/09 Content info 256 pages
Product code MAMA99910
Price From  US $ 4650 Order/Price list
US $ 4650 PDF by E-mail (Single User License)
US $ 5650 PDF by E-mail (Multi User License)
US $ 7150 PDF by E-mail (Corporate Use License)
Delivery Time
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Description TOC

Table of Contents

1. CHAPTER ONE: INTRODUCTION

2. Chapter two: Summary

3. Chapter three: Market overview

  • 3.1. Driving factor analysis of Global biomaterial market
  • 3.2. Defining the global biomaterial market
  • 3.3. DEFINING The biomaterial DEVICE MARKET
  • 3.4. Market drivers of biomaterial market
    • 3.4.1. new and improved technologies
    • 3.4.2. Advances in understanding of elementary biocompatibility science
    • 3.4.3. Large application area
    • 3.4.4. Introduction of bio-absorbable biomaterial products
    • 3.4.5. Rising awareness
    • 3.4.6. Development of synthetic biomaterials for medical applications
    • 3.4.7. increase in aging population
    • 3.4.8. Medical insurance coverage
    • 3.4.9. Recent development in biomaterial research
    • 3.4.10. Heightened interest in personal healthcare
  • 3.5. Market inhibitors
    • 3.5.1. Lack of tissue availability
    • 3.5.2. Lack of proper reimbursement facilities
  • 3.6. Opportunities
    • 3.6.1. Streamlining issues in partnerships
    • 3.6.2. Market participation by smaller companies
    • 3.6.3. Growing need for integrated and combined materials
    • 3.6.4. Development of new intelligent materials with dynamic molecular functions
    • 3.6.5. Emerging preference for minimally invasive surgery

4. Chapter four: biomaterial product market

  • 4.1. Orthopedic biomaterial market
    • 4.1.1. Market drivers
      • 4.1.1.1. Product penetration
      • 4.1.1.2. Increase in demand for orthopedic biomaterial products in spine surgery
      • 4.1.1.3. Easy surgical procedures
    • 4.1.2. Market inhibitors
      • 4.1.2.1. Economic constraints
      • 4.1.2.2. Increase in competition has led to lesser profit margin
    • 4.1.3. Opportunities
      • 4.1.3.1. Spinal treatment expected to be on the rise
    • 4.1.4. Top player analysis of orthopedic biomaterial market
    • 4.1.5. Orthopedic reconstructive
      • 4.1.5.1. Market drivers
        • 4.1.5.1.1. Availability of a wide range of products for specific application
      • 4.1.5.1.2. New materials with improved properties are developed to create demand
      • 4.1.5.2. Market inhibitors and opportunities
      • 4.1.5.3. Top Players analysis in Orthopedic Reconstructive market
      • 4.1.5.4. Artificial hip biomaterial market
        • 4.1.5.4.1. Cemented prostheses biomaterial market
        • 4.1.5.4.2. Uncemented prostheses biomaterial market
      • 4.1.5.5. Artificial knee biomaterial market
        • 4.1.5.5.1. Non-constraint implants
        • 4.1.5.5.2. Semi-constraint implants
        • 4.1.5.5.3. Constraint implants
    • 4.1.6. Trauma biomaterial product market
      • 4.1.6.1. Market Drivers
        • 4.1.6.1.1. Sports and other accidents are fuelling the trauma market
        • 4.1.6.1.2. Innovation is a growth factor in trauma market
        • 4.1.6.1.3. Plate and screw systems are driving the growth
      • 4.1.6.2. Top Players analysis of Trauma Orthopedic biomaterial market
    • 4.1.7. Orthobiologics
      • 4.1.7.1. Top player analysis of orthobiologics biomaterial market
      • 4.1.7.2. DBM
      • 4.1.7.3. Machined bone allografts
      • 4.1.7.4. Non proprietary allografts
      • 4.1.7.5. Synthetic bone substitute
      • 4.1.7.6. Bone morphogenic protein (BMP)
      • 4.1.7.7. Platelet concentrates
    • 4.1.8. Sports medicine
      • 4.1.8.1. Market Drivers
        • 4.1.8.1.1. Varying characteristics of implants suit the needs of operative sports
        • 4.1.8.1.2. Quick healing medicines boost growth
      • 4.1.8.2. Top player analysis of sports medicine orthopedic biomaterial market
    • 4.1.9. Bone cement
      • 4.1.9.1. Market Drivers
        • 4.1.9.1.1. Lesions can be eased using bone cements
        • 4.1.9.1.2. Bone cements can be used with antibiotics
      • 4.1.9.2. Inhibitors and opportunities
      • 4.1.9.3. Top player analysis of bone cement orthopedic biomaterial market
    • 4.1.10. Spinal
      • 4.1.10.1. Drivers
        • 4.1.10.1.1. Spinal treatment for younger patients on the rise
        • 4.1.10.1.2. Motion preserving devices drives growth
      • 4.1.10.2. Inhibitors
      • 4.1.10.3. Opportunities
      • 4.1.10.4. Top player analysis of spine orthopedic biomaterial market
      • 4.1.10.5. Cervical
      • 4.1.10.6. Lumbar
    • 4.1.11. Dental
      • 4.1.11.1. Drivers
        • 4.1.11.1.1. Advantages of implants over dentures and bridges
        • 4.1.11.1.2. Implants last lifelong
      • 4.1.11.2. Inhibitors and opportunities
      • 4.1.11.3. Top player analysis of dental orthopedic biomaterial market
      • 4.1.11.4. Dental bone graft and substitute
      • 4.1.11.5. Allograft
      • 4.1.11.6. Xenograft
      • 4.1.11.7. Synthetic dental bone graft and substitute market
      • 4.1.11.8. Tissue regeneration
      • 4.1.11.9. Dental membranes
  • 4.2. Cardiovascular
    • 4.2.1. drivers
      • 4.2.1.1. Advancements in treatments
      • 4.2.1.2. Rising number of obesity cases affecting the growth of the procedures that use these products
      • 4.2.1.3. Increase in thrombosis and heart failure treatments drive growth
      • 4.2.1.4. Vascular surgery market is growing with the uses of biomaterials
    • 4.2.2. Inhibitors and opportunities
    • 4.2.3. Top player analysis of cardiovascular biomaterials market
    • 4.2.4. Cardiac pacemakers biomaterial market
      • 4.2.4.1. Top player analysis of cardiac pacemaker cardiovascular biomaterial market
    • 4.2.5. Implantable Cardioverter Defibrillator
      • 4.2.5.1. Top player analysis of implantable cardioverter defibrillator cardiovascular biomaterial market
    • 4.2.6. Cardiac Stent
      • 4.2.6.1. Top player analysis of cardiac stents biomaterial market
    • 4.2.7. Artificial heart valves
      • 4.2.7.1. Top player analysis of artificial heart valve cardiovascular biomaterial market
    • 4.2.8. Vascular Access devices
      • 4.2.8.1. Market Drivers
        • 4.2.8.1.1. Demand for advanced cardiac care in developing countries
        • 4.2.8.1.2. Eliminates repeated needle sticks
      • 4.2.8.2. Inhibitors and opportunities
      • 4.2.8.3. Top player analysis of vascular access devices biomaterial market
    • 4.2.9. Peripheral vascular grafts
  • 4.3. Wound care products
    • 4.3.1. drivers
      • 4.3.1.1. Multiple advantages over conventional wound care products
      • 4.3.1.2. Supports healing process of the skin
      • 4.3.1.3. Advanced gel based products help accelerate the healing of wounds in special category of patients
      • 4.3.1.4. Prevention of bacterial colonization on sutures
      • 4.3.1.5. Reduction in the cost of hospitalization
      • 4.3.1.6. Eliminates frequent change of dressings
      • 4.3.1.7. Increase in Diabetes foot ulcer
    • 4.3.2. Inhibitors
    • 4.3.3. Opportunities
      • 4.3.3.1. Increase in penetration of negative pressure wound therapy outside the U.S.
      • 4.3.3.2. Introduction of more efficient and cost effective therapies
      • 4.3.3.3. Usage of natural polymer biomaterials for stability in treatment
    • 4.3.4. Top player analysis of wound care biomaterial market
    • 4.3.5. Internal tissue sealant
      • 4.3.5.1. Drivers
        • 4.3.5.1.1. Technological advances
        • 4.3.5.1.2. Wide range of applications and features
        • 4.3.5.1.3. Faster healing
      • 4.3.5.2. Top player analysis of internal tissue sealant wound care biomaterial market
      • 4.3.5.3. Fibrin Sealants
      • 4.3.5.4. Synthetic sealants
    • 4.3.6. Surgical Hemostats
      • 4.3.6.1. Market Drivers
        • 4.3.6.1.1. New surgical hemostats provide improved control of bleeding
        • 4.3.6.1.2. Reduces the need for frequent blood transfusions
      • 4.3.6.2. Inhibitors and opportunities
      • 4.3.6.3. Top player analysis of surgical hemostats market
      • 4.3.6.4. Thrombin-based hemostats
      • 4.3.6.5. Oxidized regenerated cellulose based topical hemostats
      • 4.3.6.6. Gelatin-based hemostats
      • 4.3.6.7. Combination hemostats
      • 4.3.6.8. Collagen based hemostats
      • 4.3.6.9. Autologous based hemostats
      • 4.3.6.10. Polysaccharide based hemostats
    • 4.3.7. Adhesion barriers
      • 4.3.7.1. Drivers
        • 4.3.7.1.1. Absorbable barriers are developed for surgeries
        • 4.3.7.1.2. Reduces adhesion probability
      • 4.3.7.2. Inhibitors and opportunities
      • 4.3.7.3. Top player analysis of adhesion prevention wound care biomaterial market
      • 4.3.7.4. Films
      • 4.3.7.5. Gels
    • 4.3.8. Skin substitutes
    • 4.3.9. drivers
      • 4.3.9.1. Increased incidences of gastro-intestinal diseases
      • 4.3.9.2. FDA approval for shifting gastrointestinal drugs from prescription drugs to over-the-counter
    • 4.3.10. Inhibitors
      • 4.3.10.1. Lack of awareness of probiotic cultured materials
    • 4.3.11. Opportunities
      • 4.3.11.1. New developments coming up in gastrointestinal wound healing
    • 4.3.12. Top player analysis of gastrointestinal biomaterial market
  • 4.4. Urological market
    • 4.4.1. drivers
      • 4.4.1.1. Availability of biodegradable materials for treatment
      • 4.4.1.2. Development of scaffolds for the treatment of several disorders
    • 4.4.2. Inhibitors and Opportunities
    • 4.4.3. Top player analysis of urological biomaterial market
    • 4.4.4. Urological stents
      • 4.4.4.1. Market Drivers
        • 4.4.4.1.1. Stents are used in short duration treatment
        • 4.4.4.1.2. Broad indications and growing population boost the market
      • 4.4.4.2. Inhibitors and Opportunities
    • 4.4.5. Urological catheters
      • 4.4.5.1. Drivers
        • 4.4.5.1.1. New approach in catheter design has set performance standards to increase demand
        • 4.4.5.1.2. Increased applicability of catheters boost the market
      • 4.4.5.2. Inhibitors
      • 4.4.5.3. Opportunities
        • 4.4.5.3.1. Use of biomaterials in catheters eliminates certain disadvantages
        • 4.4.5.3.2. Biocompatibility of chemicals can be improved in catheters
      • 4.4.5.4. Dialysis catheter
        • 4.4.5.4.1. Top player analysis of dialysis catheter market
      • 4.4.5.5. Hemodialysis catheter
      • 4.4.5.6. Peritonial catheter
      • 4.4.5.7. Urinary catheter
      • 4.4.5.8. Indwelling catheter
      • 4.4.5.9. External catheter
      • 4.4.5.10. Intermittent catheter
  • 4.5. Plastic surgery
    • 4.5.1. Market Drivers
      • 4.5.1.1. More surgeons are moving towards plastic surgery market from reconstructive procedures
      • 4.5.1.2. Cultural factors boost the market growth
      • 4.5.1.3. Baby boomers to boost the market growth
    • 4.5.2. Market Inhibitors
      • 4.5.2.1. Difficulties in treating craniofacial trauma
    • 4.5.3. Opportunities
      • 4.5.3.1. Market has not tapped men for facial surgeries
      • 4.5.3.2. Development of advanced procedures for quick patient recovery
    • 4.5.4. Top player analysis of plastic surgery biomaterial market
    • 4.5.5. Breast Implants
      • 4.5.5.1. Drivers
        • 4.5.5.1.1. More refined procedures are available
        • 4.5.5.1.2. Choices available for breast implants are wider
      • 4.5.5.2. Inhibitors
      • 4.5.5.3. Opportunities
        • 4.5.5.3.1. Reduction in complications will be an opportunity
        • 4.5.5.3.2. Safety issues need to be addressed
      • 4.5.5.4. Top player analysis of breast implants biomaterial market
      • 4.5.5.5. Saline filled implants
      • 4.5.5.6. Silicone filled implants
    • 4.5.6. Injectable fillers
      • 4.5.6.1. Drivers
        • 4.5.6.1.1. Anti-aging has driven the market growth
        • 4.5.6.1.2. Permanent results can be achieved using fillers
      • 4.5.6.2. Inhibitors
        • 4.5.6.2.1. Allergy reaction and re-absorption is a concern in injectable fillers
      • 4.5.6.3. Opportunities
        • 4.5.6.3.1. FDA approval not needed for fat fillers
      • 4.5.6.4.Top player analysis of injectable fillers biomaterial market
    • 4.5.7. Facial Implants
      • 4.5.7.1. Drivers
        • 4.5.7.1.1. Iraq war increased the demand for facial implants
        • 4.5.7.1.2. Faster recovery and surgery times
      • 4.5.7.2. Inhibitors
      • 4.5.7.3. Opportunities
      • 4.5.7.4. Top player analysis of facial implants biomaterial market
  • 4.6. Other biomaterials

5. Chapter five: Biomaterial market

  • 5.1. Ceramics
    • 5.1.1. Drivers
      • 5.1.1.1. Low stress shielding
      • 5.1.1.2. No disease transmission
      • 5.1.1.3. Material supply is unlimited
    • 5.1.2. Inhibitors and opportunities
    • 5.1.3. Top player analysis of ceramics market
    • 5.1.4. Bioinert ceramics
      • 5.1.4.1. Drivers
        • 5.1.4.1.1. Can be used for high strength applications
        • 5.1.4.1.2. They show high chemical stability
      • 5.1.4.2. Inhibitors
      • 5.1.4.3. Opportunities
        • 5.1.4.3.1. Alumina
        • 5.1.4.3.2. Drivers
        • 5.1.4.3.3. Inhibitors
        • 5.1.4.3.4. Opportunities
      • 5.1.4.4. Zirconia ceramic
        • 5.1.4.4.1. Drivers
        • 5.1.4.4.2. Inhibitors
        • 5.1.4.4.3. Opportunities
      • 5.1.4.5. Other bioinert ceramics market
    • 5.1.5. Bioactive ceramics
      • 5.1.5.1. Drivers
        • 5.1.5.1.1. They help in bone formation
        • 5.1.5.1.2. They bond with living bone tissue
        • 5.1.5.1.3. Inhibitors and Opportunities
      • 5.1.5.2. Bioglass
        • 5.1.5.2.1. Drivers
        • 5.1.5.2.2. Inhibitors
        • 5.1.5.2.3. Opportunities
      • 5.1.5.3. Other bioactive ceramics market
    • 5.1.6. Biodegradable ceramics
      • 5.1.6.1. Drivers
        • 5.1.6.1.1. They are the least toxic of ceramics
        • 5.1.6.1.2. The degradable rate can be tailored
      • 5.1.6.2. Inhibitors and opportunities
      • 5.1.6.3. Hydroxyapetite
        • 5.1.6.3.1. Drivers
        • 5.1.6.3.2. Inhibitors
        • 5.1.6.3.3. Opportunity
    • 5.1.6.4.Others biodegradable biomaterial market
  • 5.2. Metals
    • 5.2.1. Drivers
      • 5.2.1.1. Balancing act of metallic biomaterials
      • 5.2.1.2. Improved properties of metallic biomaterials
    • 5.2.2. Inhibitors
    • 5.2.3. Opportunities
      • 5.2.3.1. Improvement in corrosion resistance
      • 5.2.3.2. Introduction of new alloys
    • 5.2.4. Top player analysis of metallic biomaterial market
    • 5.2.5. Pure form metals
      • 5.2.5.1. Titanium
      • 5.2.5.2. Gold
      • 5.2.5.3. Silver
      • 5.2.5.4. Platinum
    • 5.2.6. Alloys
      • 5.2.6.1. Drivers
        • 5.2.6.1.1. Availability of ore for biomaterials manufacture
        • 5.2.6.1.2. Can be sterilized easily
      • 5.2.6.2. Inhibitors and opportunities
      • 5.2.6.3. Top player analysis of alloy biomaterial market
      • 5.2.6.4. High Carbon Cobalt Chromium alloy
  • 5.3. Polymers
    • 5.3.1. Drivers
      • 5.3.1.1. Biodegradable naturally
      • 5.3.1.2. Compatibility in imaging
    • 5.3.2. Inhibitors and opportunities
    • 5.3.3. Top player analysis of polymer biomaterial market
    • 5.3.4. Natural polymers
      • 5.3.4.1. Drivers
        • 5.3.4.1.1. They are safe for use
        • 5.3.4.1.2. They work at a molecular level
      • 5.3.4.2. Inhibitors and opportunities
      • 5.3.4.3. Collagen Market
      • 5.3.4.4. Chitosan
      • 5.3.4.5. Alginate
      • 5.3.4.6. Others natural polymers
    • 5.3.5. Synthetic polymers
      • 5.3.5.1. PLA/PGA
      • 5.3.5.2. PTFE (polytetrafluoroethylene)
      • 5.3.5.3. Other synthetic polymers

6. Chapter Six: Application market

  • 6.1. General surgery
    • 6.1.1. Drivers
      • 6.1.1.1. Suturing has become easier with the synthetic biomaterials
      • 6.1.1.2. Stringent requirements of surgeons are met by biomaterials
      • 6.1.1.3. Biomaterials are used as adhesion prevention materials
    • 6.1.2. Inhibitors
    • 6.1.3. Opportunities
      • 6.1.3.1. The development of a permanent solution for adhesion prevention
      • 6.1.3.2. Properties of biomaterials can be improved to increase usage
  • 6.2. Surgical Appliances and supplies
    • 6.2.1. Drivers
      • 6.2.1.1. Advanced materials for surgical appliances drives growth
      • 6.2.1.2. Surgical advances in orthopedic and prosthetic applications
      • 6.2.1.3. Increased healthcare spending by developed countries
      • 6.2.1.4. Tissue engineering doesn' t have any side effects
      • 6.2.1.5. Biomaterials are used to accelerate natural phenomena
    • 6.2.2. Market Inhibitors
      • 6.2.2.1. Reduced availability of outside capital
      • 6.2.2.2. Tissue engineering may require reoperation
      • 6.2.2.3. The process of approving is slow
    • 6.2.3. Opportunities
      • 6.2.3.1. Demographic factors will provide growth
      • 6.2.3.2. Increase in export opportunities
      • 6.2.3.3. Development of artificial organs in future
      • 6.2.3.4. Treatment of sleep disorder is under investigation
  • 6.3. Drug delivery applications
    • 6.3.1. Drivers
      • 6.3.1.1. Enabling properties of biomaterials drive growth
      • 6.3.1.2. Most of the biomaterials are bio-absorbable
      • 6.3.1.3. Quick and effective methods have been developed
    • 6.3.2. Inhibitors
    • 6.3.3. Opportunities
  • 6.4. Dental products
    • 6.4.1. Drivers
      • 6.4.1.1. Biomaterials have wider dental applications
      • 6.4.1.2. Risk of dental disease is set to increase
      • 6.4.1.3. Improvement in polymers used for dental applications
    • 6.4.2. Inhibitors
    • 6.4.3. Opportunities
  • 6.5. Surgical and Medical Instruments
    • 6.5.1. Drivers
      • 6.5.1.1. Breakthrough in innovations of surgical instruments drive growth
      • 6.5.1.2. Availability of cheap surgical instruments
    • 6.5.2. Inhibitors
    • 6.5.3. Opportunities
  • 6.6. Electro medical equipment application
    • 6.6.1. Drivers
      • 6.6.1.1. There is a substantial increase in the number of patients
      • 6.6.1.2. Demand for efficient procedures and economies of scale
    • 6.6.2. Inhibitors
      • 6.6.2.1. Polymers used in the equipment are prone to release toxic agents
      • 6.6.2.2. There is a possibility of electrical leakage
    • 6.6.3. Opportunities
  • 6.7. Other applications

7. Chapter Seven: Geographic Analysis of biomaterial market

8. Chapter eight: Company profiles

  • 8.1. 3DM, Inc.
  • 8.2. AdvanSource Biomaterials Corporation
  • 8.3. Allergan Inc.
  • 8.4. AlloSource
  • 8.5. Alphatec Spine, Inc.
  • 8.6. Amedica Corporation
  • 8.7. Angiotech Pharmaceuticals, Inc.
  • 8.8. ApaTech Ltd.
  • 8.9. Artimplant AB
  • 8.10. Biocoral, Inc.
  • 8.11. BioInteractions Ltd.
  • 8.12. Bioretec Ltd.
  • 8.13. Bio Syntech Canada Inc.
  • 8.14. Boston Scientific Corporation
  • 8.15. Collagen Matrix, Inc.
  • 8.16. Corin Group PLC
  • 8.17. Covalon technologies
  • 8.18. CryoLife Inc.
  • 8.19. Davol, Inc.
  • 8.20. Depuy Orthopaedics Inc.
  • 8.21. ETEX Corporation
  • 8.22. Forticell Bioscience, Inc.
  • 8.23. Genzyme Biosurgery
  • 8.24. Haemacure Corporation
  • 8.25. Inion Oy
  • 8.26. Integra Lifesciences Holdings Corp.
  • 8.27. International Biocomposites Ltd.
  • 8.28. Invibio Ltd.
  • 8.29. ISTO Technologies, Inc.
  • 8.30. Kensey Nash Corporation
  • 8.31. Medtronic, Inc.
  • 8.32. Mentor Corporation
  • 8.33. MIV Therapeutics Inc.
  • 8.34. Olympus Terumo Biomaterials Ltd.
  • 8.35. Organogenesis, Inc.
  • 8.36. Orthovita
  • 8.37. Osteotech, Inc.
  • 8.38. Pioneer Surgical Technology
  • 8.39. Polymer Technology Group
  • 8.40. Protein Polymer Technologies Inc.
  • 8.41. RTI Biologics, Inc.
  • 8.42. Smith & Nephew plc
  • 8.43. Stryker Corporation
  • 8.44. Synthes, Inc.
  • 8.45. TEI Biosciences
  • 8.46. TORNIER Inc.
  • 8.47. Vygon S.A
  • 8.48. W.L. Gore & Associates Inc.
  • 8.49. Wright Medical Group, Inc.
  • 8.50. Zimmer Holding, Inc.

9. Chapter nine: Patent analysis

Appendix

  • 1. U.S. biomaterial product patents
  • 2. Europe biomaterial product patents
  • 3. Asia biomaterial product patents
  • 4. U.S. biomaterial patents
  • 5. Europe biomaterial patent
  • 6. Asia biomaterial patents

List of Tables

  • Summary Table Global biomaterial market, by products 2007 - 2014 ($ million)
  • TABLE 1 GLOBAL orthopedic BIOMATERIAL DEVICE MARKET, BY TYPES 2007 - 2014 ($ million)
  • TABLE 2 GLOBAL orthopedic biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 3 GLOBAL orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 4 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 5 GLOBAL reconstructive orthopedic BIOMATERIAL DEVICE MARKET, BY TYPES 2007 - 2014 ($ million)
  • TABLE 6 GLOBAL reconstructive orthopedic biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 7 GLOBAL reconstructive orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 8 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 9 GLOBAL artificial hip orthopedic biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 10 GLOBAL artificial hip orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 11 GLOBAL cemented prostheses orthopedic biomaterial MARKET, BY geography2007 - 2014 ($ million)
  • TABLE 12 GLOBAL uncemented prostheses orthopedic biomaterial MARKET, BY geography, 2007 - 2014 ($ million)
  • TABLE 13 GLOBAL artificial knee orthopedic biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 14 GLOBAL artificial knee orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 15 GLOBAL non-constrainT implants orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ millions)
  • TABLE 16 GLOBAL semi-constrainT orthopedic biomaterials MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 17 GLOBAL constrainT implants orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 18 GLOBAL trauma orthopedic BIOMATERIAL DEVICE MARKET, BY TYPES 2007 - 2014 ($ million)
  • TABLE 19 GLOBAL trauma orthopedic biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 20 GLOBAL trauma orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 21 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 22 GLOBAL orthobiologics biomaterial MARKET, BY device 2007 - 2014 ($ million)
  • TABLE 23 GLOBAL orthobiologics biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 24 GLOBAL orthobiologics biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 25 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 26 GLOBAL DBM orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 27 GLOBAL machined bone allograft orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 28 GLOBAL non proprietary allograft orthopedic MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 29 GLOBAL synthetic bone substitute orthopedic biomaterials MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 30 GLOBAL BMP orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 31 GLOBAL platelet concentrates orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 32 GLOBAL sports medicine orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 33 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 34 GLOBAL bone cement orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 35 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 36 GLOBAL spine orthopedic biomaterial MARKET, BY device 2007 - 2014 ($ million)
  • TABLE 37 GLOBAL spine orthopedic biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 38 GLOBAL spine orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 39 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 40 GLOBAL cervical spine orthopedic biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 41 GLOBAL cervical spine orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 42 GLOBAL lumbar spine orthopedic biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 43 GLOBAL lumbar spine orthopedic biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 44 GLOBAL dental orthopedic BIOMATERIAL DEVICE MARKET, BY TYPES 2007 - 2014 ($ million)
  • TABLE 45 GLOBAL dental orthopedic biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 46 GLOBAL dental orthopedic biomaterials MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 47 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 48 GLOBAL dental bone graft orthopedic biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 49 GLOBAL dental bone graft orthopedic biomaterial MARKET, BY geography, 2007 - 2014 ($ million)
  • TABLE 50 GLOBAL dental allograft orthopedic biomaterial MARKET, BY geography, 2007 - 2014 ($ million)
  • TABLE 51 GLOBAL xenograft dental biomaterial MARKET, BY geography, 2007 - 2014 ($ million)
  • TABLE 52 GLOBAL synthetic dental biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 53 GLOBAL tissue regeneration dental biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 54 GLOBAL dental membrane biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 55 GLOBAL cardiovascular biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 56 GLOBAL cardiovascular biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 57 GLOBAL cardiovascular biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 58 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 59 GLOBAL cardiac pacemaker cardiovascular device MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 60 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 61 GLOBAL implantable cardioverter defibrillator cardiovascular biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 62 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 63 GLOBAL cardiac stents cardiovascular biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 64 GLOBAL cardiac stents cardiovascular biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 65 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 66 GLOBAL artificial heart valve cardiovascular biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 67 GLOBAL artificial heart valve cardiovascular biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 68 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 69 GLOBAL vascular access devices cardiovascular biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 70 GLOBAL vascular access devices cardiovascular biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 71 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 72 GLOBAL peripheral vascular grafts MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 73 GLOBAL wound care BIOMATERIAL DEVICE MARKET, BY TYPES 2007 - 2014 ($ million)
  • TABLE 74 GLOBAL wound care biomaterial MARKET, BY PRODUCTS, 2007 - 2014 ($ million)
  • TABLE 75 GLOBAL wound care biomaterial MARKET, BY geography2007 - 2014 ($ million)
  • TABLE 76 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 77 GLOBAL internal tissue sealant wound care biomaterial MARKET, BY PRODUCTS, 2007 - 2014 ($ million)
  • TABLE 78 GLOBAL internal tissue sealant wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 79 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 80 GLOBAL fibrin-based sealant wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 81 GLOBAL synthetic based sealant wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 82 GLOBAL surgical hemostats wound care biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 83 GLOBAL surgical hemostats wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 84 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 85 GLOBAL thrombin based hemostats wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 86 GLOBAL oxidized regenerated cellulose based hemostats wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 87 GLOBAL gelatin based hemostats wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 88 GLOBAL combination hemostats wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 89 GLOBAL collagen based hemostats wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 90 GLOBAL autologous based hemostats wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 91 GLOBAL polysaccharide based hemostats wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 92 GLOBAL adhesion barriers wound care MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 93 GLOBAL adhesion barriers wound care MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 94 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 95 GLOBAL films wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 96 GLOBAL gels wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 97 GLOBAL skin substitute wound care biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 98 GLOBAL gastrointestinal biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 99 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 100 GLOBAL urological BIOMATERIAL DEVICE MARKET, BY TYPES 2007 - 2014 ($ million)
  • TABLE 101 GLOBAL urological biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 102 GLOBAL urological biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 103 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 104 GLOBAL stents urological biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 105 GLOBAL catheter urological biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 106 GLOBAL catheters urological biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 107 GLOBAL dialysis catheter urological BIOMATERIAL DEVICE MARKET, BY TYPES 2007 - 2014 ($ million)
  • TABLE 108 GLOBAL dialysis catheter urological biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 109 GLOBAL dialysis catheter urological biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 110 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 111 GLOBAL hemodialysis catheter urological biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 112 GLOBAL peritonial catheter urological biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 113 GLOBAL urinary catheter urological BIOMATERIAL DEVICE MARKET, BY TYPES 2007 - 2014 ($ million)
  • TABLE 114 GLOBAL urinary catheter urological biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 115 GLOBAL urinary catheters urological biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 116 GLOBAL indwelling catheter urological biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 117 GLOBAL plastic surgery biomaterial device MARKET, BY types 2007 - 2014 ($ million)
  • TABLE 118 GLOBAL plastic surgery biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 119 GLOBAL plastic surgery biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 120 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 121 GLOBAL breast implants plastic surgery BIOMATERIAL DEVICE MARKET, BY TYPES 2007 - 2014 ($ million)
  • TABLE 122 GLOBAL breast implants plastic surgery biomaterial MARKET, BY PRODUCTS 2007 - 2014 ($ million)
  • TABLE 123 GLOBAL breast implants plastic surgery biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 124 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 125 GLOBAL saline filled implants breast implant biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 126 GLOBAL silicone gel implants breast implant biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 127 GLOBAL injectable fillers breast implant biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 128 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 129 GLOBAL facial implants plastic surgery biomaterial MARKET, BY geography 2007 - 2014 ($ million)
  • TABLE 130 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • TABLE 131 GLOBAL biomaterial MARKET, BY types 2007 - 2014 ($ million)
  • TABLE 132 GLOBAL ceramics MARKET, BY types of biomaterials 2007 - 2014 ($ million)
  • TABLE 133 MAJOR PLAYERS AND THEIR RESPECTIVE DEVELOPMENTS
  • Table 134 Technological advancements in ceramics market
  • TABLE 135 GLOBAL bioinert ceramics MARKET, BY types of biomaterials 2007 - 2014 ($ million)
  • TABLE 136 GLOBAL bioactive ceramics MARKET, BY types 2007 - 2014 ($ million)
  • TABLE 137 GLOBAL biodegradable ceramics MARKET, BY types 2007 - 2014 ($ million)
  • TABLE 138 GLOBAL metallic biomaterial MARKET, BY types 2007 - 2014 ($ million)
  • TABLE 139 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 140 GLOBAL pure form metals MARKET, BY types 2007 - 2014 ($ million)
  • TABLE 141 GLOBAL alloy biomaterial MARKET, BY types 2007 - 2014 ($ million)
  • TABLE 142 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 143 GLOBAL polymer biomaterials MARKET, BY types 2007 - 2014 ($ million)
  • TABLE 144 MAJOR PLAYERS AND THEIR RESPECTIVE PRODUCT DEVELOPMENTS
  • TABLE 145 GLOBAL natural polymer biomaterial MARKET, BY types 2007 - 2014 ($ million)
  • TABLE 146 GLOBAL synthetic polymer biomaterial MARKET, BY types of biomaterials 2007 - 2014 ($ million)
  • TABLE 147 Application market for biomaterials
  • TABLE 148 Global biomaterial market, by geography, 2007 - 2014 ($ million)
  • TABLE 149 U.S. biomaterial market, by products, 2007 - 2014($ million)
  • TABLE 150 European biomaterial market, by products, 2007 - 2014 ($ million)
  • TABLE 151 Asian biomaterial market, by products, 2007 - 2014 ($ million)
  • TABLE 152 3dm, inc. Product profile
  • TABLE 153 3dm, inc. strategy
  • TABLE 154 AdvanSource Biomaterials Corporation product profile
  • TABLE 155 allergan inc. Product profile
  • TABLE 156 allosource Product profile
  • TABLE 157 allosource strategy
  • TABLE 158 Alphatec Spine, Inc. Product profile
  • TABLE 159 Alphatec Spine, Inc. strategies and developments
  • TABLE 160 amedica corporation Product profile
  • TABLE 161 amedica corporation Developments
  • TABLE 162 Angiotech pharmaceuticals, Inc. Product profile
  • TABLE 163 Angiotech pharmaceuticals, Inc. Strategy
  • TABLE 164 apatech ltd. Product profile
  • TABLE 165 artimplant ab product profile
  • TABLE 166 artimplant ab strategies and developments
  • TABLE 167 Biointeractions Ltd. product profile
  • TABLE 168 bioretec ltd. product profile
  • TABLE 169 bio syntech canada inc. product profile
  • TABLE 170 bio syntech canada inc. Strategy
  • TABLE 171 Boston scientific CORPORATION PRODUCT profile
  • TABLE 172 Collagen matrix, Inc. Product profile
  • TABLE 173 Collagen matrix, Inc. Strategy
  • TABLE 174 Corin group, plc. Product profile
  • TABLE 175 Covalon technologies Product profile
  • TABLE 176 Covalon strategy
  • TABLE 177 CryoLife Inc, Product Profile
  • TABLE 178 CryoLife Inc., strategy
  • TABLE 179 davol, Inc. Product profile
  • TABLE 180 davol, Inc. Strategy
  • TABLE 181 DePuy Orthopedics, Inc. Product profile
  • TABLE 182 DePuy Orthopedics, Inc. Strategy
  • TABLE 183 etex corporation Product profile
  • TABLE 184 Etex corporation strategies and developments
  • TABLE 185 Genzyme Biosurgery Product profile
  • TABLE 186 Genzyme Biosurgery Developments
  • TABLE 187 nion oy Product profile
  • TABLE 188 ntegra Life sciences Holdings Corp. product profile
  • TABLE 189 ntegra Life sciences Holdings Corp. strategy
  • TABLE 190 International Biocomposites ltd. Product profile
  • TABLE 191 International Biocomposites ltd. Developments
  • TABLE 192 invibio ltd. Product profile
  • TABLE 193 invibio ltd. strategy
  • TABLE 194 isto technologies, inc. applications
  • TABLE 195 Kensey Nash corporation Product profile
  • TABLE 196 medtronic Inc. Product Profile
  • TABLE 197 Medtronic inc. strategies & developments
  • TABLE 198 mentor corporation Product profile
  • TABLE 199 MIV Therapeutics Inc. Product Profile
  • TABLE 200 Olympus Terumo product profile
  • TABLE 201 Olympus Terumo Strategy
  • TABLE 202 organogenesis, Inc. Product profile
  • TABLE 203 orthovita product profile
  • TABLE 204 osteotech, Inc. Product profile
  • TABLE 205 Pioneer Surgical Technology Product profile
  • TABLE 206 Pioneer Surgical Technology strategy
  • TABLE 207 Polymer Technology Group profile
  • TABLE 208 Protein polymer technologies, Inc. Product profile
  • TABLE 209 RTI biologics product profile
  • TABLE 210 RTI biologics Strategies
  • TABLE 211 smith & nephew plc Product profile
  • TABLE 212 smith & nephew plc strategy
  • TABLE 213 Stryker Corporation product profile
  • TABLE 214 Synthes inc. product profile
  • TABLE 215 Synthes inc. Strategy
  • TABLE 216 Tei biosciences Product profile
  • TABLE 217 tornier inc. product profile
  • TABLE 218 tornier inc. strategy
  • TABLE 219 vygon s.a Product profile
  • TABLE 220 vygon s.a strategy
  • TABLE 221 W.L. Gore & Associates Inc. Product profile
  • TABLE 222 Wright medical group, inc. product profile
  • TABLE 223 Wright medical group, inc. Developments
  • TABLE 224 zimmer holdings, inc. Product profile
  • TABLE 225 zimmer holdings, inc. strategy

List of Figures

  • Figure 1 Evolution of biomaterials
  • Figure 2 PARENTAL STRUCTURE OF biomaterials
  • Figure 3 Characteristics of biomaterial science
  • Figure 4 Factors affecting the biomaterial market
  • Figure 5 Global biomaterial device market, by product (2009)
  • Figure 6 relative potential matrix for biomaterial products market (2014)
  • Figure 7 Increasing Disability with age
  • Figure 8 Increasing World' s aging population
  • Figure 9 Geographical analysis of Biomaterial market (2009)
  • Figure 10 Biomaterials patents, by geography
  • Figure 11 Biomaterials patents in 2006, by geography
  • Figure 12 Biomaterials patents in 2008 by geography

LIST OF ACRONYMS AND ABBREVIATIONS

  • 1. AAOS: American Academy of Orthopedic Surgery
  • 2. AF: Atrial Fibrillation
  • 3. BMP: Bone Morphogenic Protein
  • 4. BTB: Bone Tendon Bone
  • 5. CAGR: Compounded Annual Growth Rate
  • 6. CE: Conformité Européene
  • 7. CP: Combination Pharmacotherapy
  • 8. CMF: Craniomaxillofacial
  • 9. CRT: Cardiac Resynchronization Therapy
  • 10. CSC: Cancellous Structure Ceramics
  • 11. CT: Computed Tomography
  • 12. DBM: Demineralized Bone Matrix
  • 13. DES: Drug Eluting Stents
  • 14. ESC: Environmental Stress Cracking
  • 15. FDA: Food and Drugs Administration
  • 16. HA: Hyaluronic Acid
  • 17. ICD: Implantable Cardioverter Defibrillator
  • 18. IDE: Investigational Device Exemption
  • 19. LCP: Locking Compression Plate
  • 20. MI: Myocardial Infraction
  • 21. MRI: Magnetic Resonance Imaging
  • 22. MIS: Minimally Invasive Surgery
  • 23. MS: Multiple Sclerosis
  • 24. OTC: Over the Counter
  • 25. PEEK: Polyetheretherketone
  • 26. PICC: Peripherally Inserted Central Catheter
  • 27. PMMA: Polymethylmethacrylate
  • 28. R&D: Research and Development
  • 29. RF: Radio Frequency
  • 30. ROW: Rest of the World
  • 31. SFDA: State Food and Drugs Administration
Related Report
Back to Top
Please inform me when related publications are released
InfoWatch

US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.